Perspective Therapeutics (CATX) Stock Statistics & Valuation Metrics

Perspective Therapeutics has a market cap or net worth of $502.45M. The enterprise value is $295.87M.

Perspective Therapeutics has 113,933,430 shares outstanding. The number of shares has decreased by -2.65% in one year.

Perspective Therapeutics’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is 3.79%.

The current PE Ratio of Perspective Therapeutics is ―. Perspective Therapeutics’s PEG ratio is -0.14.

In the last 12 months, Perspective Therapeutics had revenue of 0.00 and earned -103.12M in profits. Earnings per share was -1.40.

In the last 12 months, operating cash flow was -68.39M and capital expenditures -7.94M, giving a free cash flow of -76.33M billion.

Perspective Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Perspective Therapeutics upcoming earnings date is May 19, 2026, After Close (Confirmed).

Perspective Therapeutics as a current ratio of 5.17, with Debt / Equity ratio of 0.79%

In the past 12 months, Perspective Therapeutics has paid -793.00K in taxes.

Perspective Therapeutics EV to EBITDA ratio is 19.04, with an EV/FCF ratio of -1.83.

Perspective Therapeutics has $144.74M in cash and marketable securities with $1.63M in debt, giving a net cash position of $143.11M billion.

Gross margin is -166.35%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Perspective Therapeutics is $12.64, which is 11.43% higher than the current price. The consensus rating is Strong Buy